Clinical Progress of Mati Therapeutics’ Nepafenac
Bob Butchofsky, CEO of Mati Therapeutics, updated OIS@ASCRS on the company’s punctal plug delivery system, introducing 12-week data from a Phase II multicenter clinical trial for the treatment of glaucoma. Butchofsky noted the plug could also be applied to allergies, inflammation, and dry eye disease. The company expects to file an IND for Nepafenac this summer and has its sights on running a Phase II multicenter trial of patients undergoing cataract surgery, measuring both pain and inflammation. Mati has similar goals for Difluprednate.